Your browser doesn't support javascript.
Available Compounds With Therapeutic Potential Against COVID-19: Antimicrobial Therapies, Supportive Care, and Probable Vaccines.
Kumar, Rajnish; Srivastava, Janmejai Kumar; Singh, Rachana; Siddiqui, Mohammed Haris; Mansouri, Rasha A; Abdulhakim, Jawaher A; Bin-Jumah, May N; Alkahtani, Saad; Abdel-Daim, Mohamed M; Uddin, Md Sahab.
  • Kumar R; Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Lucknow, India.
  • Srivastava JK; Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Lucknow, India.
  • Singh R; Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Lucknow, India.
  • Siddiqui MH; Department of Bioengineering, Integral University, Lucknow, India.
  • Mansouri RA; Department of Biochemistry, Faculty of Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Abdulhakim JA; Department of Medical Laboratory, Faculty of Applied Medical Sciences, Taibah University, Yanbu, Saudi Arabia.
  • Bin-Jumah MN; Department of Biology, College of Science, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
  • Alkahtani S; Department of Zoology, College of Science, King Saud University, Riyadh, Saudi Arabia.
  • Abdel-Daim MM; Department of Zoology, College of Science, King Saud University, Riyadh, Saudi Arabia.
  • Uddin MS; Pharmacology Department, Faculty of Veterinary Medicine, Suez Canal University, Ismailia, Egypt.
Front Pharmacol ; 11: 582025, 2020.
Article in English | MEDLINE | ID: covidwho-890344
ABSTRACT
The recent outbreak of the COVID-2019 (coronavirus disease 2019) due to the infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has realized the requirement of alternative therapeutics to mitigate and alleviate this lethal infection. These alternative therapies are effective when they are started at the initial stage of the infection. Some drugs that were used in previous other related infections SARS-CoV-2003 and Middle East respiratory syndrome coronavirus (MERS-CoV)-2012 could be potentially active against currently emerging SARS-CoV-2. This fact imparts some rationale of current interventions, in the absence of any specific therapeutics for SARS-CoV-2. It is imperative to focus on the available antimicrobial and adjunct therapies during the current emergency state and overcome the challenges associated with the absence of robust controlled studies. There is no established set of drugs to manage SARS-CoV-2 infected patients. However, closely following patients' conditions and responding with the dosage guidelines of available drugs may significantly impact our ability to slow down the infection. Of note, it depends upon the condition of the patients and associated comorbid; therefore, the health workers need to choose the drug combinations judiciously until COVID-19 specific drug or vaccine is developed with the collective scientific rigor. In this article, we reviewed the available antimicrobial drug, supportive therapies, and probable high importance vaccines for the COVID-19 treatment.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Clinical Practice Guide Topics: Traditional medicine / Vaccines Language: English Journal: Front Pharmacol Year: 2020 Document Type: Article Affiliation country: Fphar.2020.582025

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Clinical Practice Guide Topics: Traditional medicine / Vaccines Language: English Journal: Front Pharmacol Year: 2020 Document Type: Article Affiliation country: Fphar.2020.582025